Breast cancer (BRCA) is one of the leading causes of cancer-related death worldwide. However, the preventive intervention of this disease is often obstructed by a lack of knowledge related to BRCA, later-stage diagnosis and lack of feasible treatment options. Here, the prognostic value of Forkhead Box M1 (FOXM1) was examined in BRCA to evaluate its potential as a prognostic marker. Initially, the gene was found to be noticeably upregulated (log2FC > 4) in BRCA tissues compared to adjacent normal breast tissues. Immunohistochemistry observation also revealed higher levels of FOXM1 protein expression in BRCA samples than in normal specimens. A number of somatic mutations with 0.2 % frequency, including 8 missense mutations, were observed inside the coding region of FOXM1. Moreover, the promoter of this gene was predicted to be hypomethylated, and its structural misorientation appeared to influence the patient's clinical outcome. Furthermore, the higher level of FOXM1 expression was also linked to a lower survival rate (HR > 1) of BRCA patients. Gene co-expression and further ontology and pathway analysis revealed that co-expressed genes of FOXM1 in BRCA tissue were involved in functions related to cell cycle maintenance. Altogether, the experimental findings of this study exert that FOXM1 could be a potential prognostic and therapeutic target for BRCA.